Bupropion SR 150mg for Mood: Tolerability Profile
Bupropion sustained-release 150 mg is generally well tolerated for mood improvement, with favorable side effect profiles compared to SSRIs—particularly regarding sexual dysfunction and weight changes—though close monitoring for neuropsychiatric symptoms is essential during the first 1-2 weeks. 1, 2
Evidence-Based Tolerability Assessment
Overall Safety Profile
- Bupropion SR demonstrates good tolerability with most adverse events being mild to moderate in intensity, and no serious adverse events reported in controlled trials at the 150 mg dose 3
- The FDA label confirms efficacy at 150 mg once daily as a starting dose, with the option to remain at this dose if higher doses are not tolerated 2
- In real-world clinical studies, bupropion SR 150 mg once daily was effective and well tolerated in patients with moderate to severe depression 4
Comparative Advantages Over Other Antidepressants
Sexual dysfunction: Bupropion is associated with significantly lower rates of sexual adverse events compared to SSRIs like fluoxetine, sertraline, and particularly paroxetine 1, 5
Weight effects: Bupropion typically causes modest weight loss (mean 0.5 kg at 150 mg daily) rather than weight gain, contrasting favorably with many other antidepressants 3, 6
Somnolence: Lower rates of sedation compared to tricyclic antidepressants and similar or better than SSRIs 6
Common Adverse Events to Monitor
The most frequently reported side effects at therapeutic doses include:
- Nausea/gastrointestinal symptoms: Reported in approximately 23.5% during dose escalation, typically resolving with continued use 7
- Headache: Occurs in approximately 19.4% of patients 7
- Irritability/agitation: Reported in 9.4% of patients, often resolving spontaneously 8
- Insomnia: Can occur but is generally manageable with morning dosing 2
Critical Safety Monitoring Requirements
Suicidality surveillance: The FDA mandates close monitoring within 1-2 weeks of initiation for emergence of suicidal thoughts, agitation, irritability, or unusual behavioral changes, particularly in younger adults 1, 2
Seizure risk: While present, this risk is dose-dependent and minimized at 150 mg daily; gradual dose escalation is essential if increasing beyond this dose 2
Neuropsychiatric symptoms: Monitor for anxiety, panic attacks, hostility, impulsivity, or hypomania, especially during early treatment 2
Discontinuation Rates
- In controlled trials, discontinuation due to adverse events was numerically low at the 150 mg dose 3
- When used as augmentation therapy, bupropion SR showed lower discontinuation rates (12.5%) compared to buspirone augmentation (20.6%) 9
- Real-world studies show variable discontinuation rates, but these often reflect multiple factors beyond tolerability alone 7
Clinical Implementation Strategy
Starting approach: Begin with 150 mg once daily in the morning, which can be taken with or without food 2
Assessment timeline: Evaluate tolerability and therapeutic response within 1-2 weeks initially, then regularly through weeks 4-8 1, 2
Dose adjustment: If well tolerated but insufficient response after 4 days to 1 week, consider increasing to 300 mg daily; however, many patients respond adequately to 150 mg 2
Special Populations Requiring Dose Modification
- Hepatic impairment (mild): Consider reducing dose/frequency at baseline 2
- Renal impairment (GFR <90): Consider reducing dose/frequency 2
- Elderly patients: Generally well tolerated, though no increased suicidality risk observed in those ≥65 years 2
Common Pitfalls to Avoid
Abrupt discontinuation: When stopping 150 mg, tapering is not typically required, but monitor for withdrawal symptoms 2
MAOI interactions: Ensure at least 14 days between discontinuing MAOIs and starting bupropion, or vice versa 2
Misattributing therapeutic non-response to poor tolerability: Bupropion SR 150 mg is often well tolerated even when efficacy is suboptimal; inadequate response should prompt dose adjustment rather than automatic discontinuation 9, 3